UNITED ~~STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549~~STATES

~~FORM~~SECURITIES ~~8-K~~AND EXCHANGE COMMISSION

~~CURRENT~~WASHINGTON, ~~REPORT~~D.C. 20549

~~Pursuant~~FORM ~~to Section 13 or 15(d) of the Securities Exchange Act of 1934~~8-K

~~Date~~CURRENT ~~of Report (Date of earliest event reported): August 11, 2025~~REPORT

~~Quince~~Pursuant ~~Therapeutics,~~to ~~Inc.~~Section 13 OR 15(d)

~~(Exact name~~ of ~~Registrant~~The asSecurities ~~Specified~~Exchange inAct ~~Its~~of ~~Charter)~~1934

Delaware	001-38890	90-1024039
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)
601 Gateway BoulevardSuite 1250
South San Francisco, California		94080
(Address of Principal Executive Offices)		(Zip Code)

Date of Report (Date of earliest event reported): September 25, 2025

~~Registrant’s~~ ~~Telephone~~QUINCE ~~Number~~THERAPEUTICS, ~~Including~~INC. ~~Area Code: (415) 910-5717~~

(~~Former~~Exact ~~Name~~name orof ~~Former~~registrant ~~Address,~~as ifspecified ~~Changed~~in ~~Since~~its ~~Last Report~~charter)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Delaware

001-38890

90-1024039

(State or other jurisdiction

of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

601 Gateway Boulevard, Suite 1250

South San Francisco, California

94080

(Address of principal executive offices)

(Zip Code)

~~☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act~~ (17415) ~~CFR 240.14a~~910-~~12)~~5717

~~☐Pre-commencement communications pursuant to Rule 14d-2~~(b)Registrant’s ~~under~~telephone ~~the~~number, ~~Exchange~~including ~~Act~~area ~~(17 CFR 240.14d-2(b~~code))

~~☐Pre-commencement~~Not ~~communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))~~Applicable

~~Securities~~(Former ~~registered~~name ~~pursuant~~or toformer ~~Section~~address, ~~12(b)~~if ofchanged ~~the~~since ~~Act:~~last report.)

Title of each class		TradingSymbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		QNCX		Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

~~Indicate~~☐ byWritten ~~check~~communications ~~mark~~pursuant ~~whether~~to ~~the registrant is an emerging growth company as defined in~~ Rule ~~405~~425 ofunder the Securities Act of(17 ~~1933~~CFR (§ 230.~~405 of this chapter~~425) ~~or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).~~

~~Emerging~~☐ ~~growth~~Soliciting ~~company~~material ☐pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

If☐ anPre-commencement ~~emerging~~communications ~~growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided~~ pursuant to ~~Section~~Rule 1314d-2(ab) ofunder the Exchange Act. ☐(17 CFR 240.14d-2(b))

~~Item~~☐ ~~2.02~~Pre-commencement ~~Results~~communications ofpursuant ~~Operations~~to ~~and~~Rule ~~Financial~~13e-4(c) ~~Condition~~under the Exchange Act (17 CFR 240.13d-4(c))

OnSecurities ~~August~~registered ~~11,~~pursuant ~~2025,~~to ~~Quince Therapeutics, Inc.~~ Section 12(~~the “Company”~~b) ~~announced its financial results for the quarter ended June 30, 2025 and provided recent business highlights. A copy~~ of the ~~press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.~~Act:

The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing.


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	QNCX	The Nasdaq Stock Market LLC

~~Item~~Indicate 9by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.01405 ~~Financial~~of ~~Statements~~this ~~and~~chapter) ~~Exhibits~~or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

~~(d)~~Emerging ~~Exhibits.~~growth company ☐

Exhibit No.		Description
99.1		Press release issued by Quince Therapeutics, Inc. dated August 11, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~SIGNATURES~~Item 1.01 Entry into a Material Definitive Agreement.

~~Pursuant~~Previously, toon October 20, 2024, Quince Therapeutics, Inc. (the ~~requirements~~“Company”), ofentered into an Accession, Amendment, and Restatement Agreement to the ~~Securities~~Finance ~~Exchange~~Contract ~~Act~~dated ofJuly 24, ~~1934~~2020, by and between the ~~registrant~~Company, ~~has~~EryDel ~~duly~~Italy, ~~caused~~Inc., ~~this~~EryDel ~~report~~US, toInc., beEryDel ~~signed~~USA, onInc., ~~its~~EryDel ~~behalf~~S.p.A., byand the ~~undersigned~~European ~~hereunto~~Investment ~~duly~~Bank, ~~authorized~~in respect of an unsecured credit facility (the “EIB Facility”).

			QUINCE THERAPEUTICS, INC.
Date:	August 11, 2025	By:	/s/ Dirk Thye
		Name:Title:	Dirk ThyeChief Executive Officer and Chief Medical Officer

On September 25, 2025, the Company entered into an amendment to the EIB Facility (the “Amendment”), providing that (i) for the period from January 1, 2026 to March 31, 2026 (the “Amendment Period”), the Company’s required minimum cash balance will be reduced from EUR 14,650,000 to EUR 5,000,000 and (ii) during the Amendment Period, out of the overall 9% Deferred Interest Rate (as defined in the EIB Facility) due in respect of Tranche A and Tranche B under the EIB Facility, 1% will be converted into Fixed Rate (as defined in the EIB Facility) to be paid on March 31, 2026 in respect of Tranche A and Tranche B.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which will be filed as an exhibit to the Quarterly Report on Form 10-Q for the period ending September 30, 2025.

Item 2.03

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The disclosure included in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

QUINCE THERAPEUTICS, INC.

Date: September 26, 2025

/s/ Dirk Thye

Chief Executive Officer and Chief Medical Officer

Filing Compare · Quince Therapeutics, Inc.